Spectrum Pharmaceuticals, Inc. Sales Agreements
14 Contracts & Agreements
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on April 5, 2010)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on April 5, 2010)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on April 5, 2010)
- Maximizing the growth potential for our marketed drugs, Fusilev and Zevalin. The companys near-term outlook depends on sales and marketing successes associated with our two... (Filed With SEC on March 31, 2009)
- Maximizing the growth potential for our marketed drugs, Fusilev and Zevalin. The companys near-term outlook depends on sales and marketing successes associated with our two... (Filed With SEC on March 31, 2009)
- Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co (Filed With SEC on October 24, 2001)
- Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co (Filed With SEC on October 24, 2001)
- Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co (Filed With SEC on October 24, 2001)
